Evidence map›Paper›PMID 40190653›Full record

ReviewFrontiers in plant science2025

Rethinking progress: harmonizing the discourse on genetically modified crops.

Abreham Bekele-Alemu, Obssi Dessalegn-Hora, Tura Safawo-Jarso, Ayalew Ligaba-Osena

Abstract readReview
In one paragraph

Review in Frontiers in plant science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Abreham Bekele-AlemuLaboratory of Plant Molecular Biology and Biotechnology, Department of Biology, University of North Carolina Greensboro, Greensboro, NC, United States.
Obssi Dessalegn-HoraEthiopian Agricultural Research Institute, National Agricultural Biotechnology Research Center, Addis Ababa, Ethiopia.
Tura Safawo-JarsoDepartment of Biology, College of Natural Sciences, Salale University, Fiche, Ethiopia.
Ayalew Ligaba-OsenaLaboratory of Plant Molecular Biology and Biotechnology, Department of Biology, University of North Carolina Greensboro, Greensboro, NC, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Genetically modified crops (GM crops) also known as biotech crops are crops that have been altered through genetic engineering techniques and under cultivation for approximately 28 years. By October 2024, over 30 nations have approved the cultivation of GM crops. The global area utilized for biotech crop production has reached 206.3 million hectares. Despite the substantial growth in the cultivation of these crops, debate continues between proponents and opponents of GM crops. In this article, critical concerns and common ground between the arguments of both sides were described. The main issues addressed include the naturalness of GM crops, religious perspectives, beneficial aspects, safety issues, socio-economic impacts and intellectual property rights. We argue that the classification GM crops as unnatural is a claim that lacks scientific reality. In a similar vein, comparing GM technology to the act of playing God is inappropriate. Moreover, the belief that GM crops do not contribute to yield improvements is inconsistent with empirical evidence. Additionally, the claim that foods produced from GM crops are unsafe for human consumption holds unseen concerns that is not on the ground. We have also highlighted the necessity of implementing intellectual property rights that support seed developers for a limited duration without violating farmers' rights. In conclusion, as a consumer has the right to know what they eat, labeling of GM food products fosters transparency and enhance consumer autonomy.

Indexed as

biotech cropsGM cropsIPRssafety concernsterminator technology

Identifiers

PMID40190653
PMCPMC11968767

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.